Clinical Research Malaysia (CRM) – Dr. Mohamed Ali Abu Bakar, CEO
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
Institut Jantung Negara (IJN) was established in 1992, as a cardiovascular and thoracic center. It has always tried to keep abreast with current advances and benchmarked with internationally acclaimed, established, advanced centers.
It has kept itself of international standards in quality in healthcare, presently accredited Joint Commission International JCI, Malaysian Society for Quality in Healthcare MSQH 3rd edition 2008 and ISO 9001:2008.
In our attempts to keep abreast with advances in cardiovascular and thoracic medicine, some of the recent procedures, surgeries, services, program are illustrated below:
Services:
Catheter-based Mitral Valve Repair with the MITRACLIP
Mitral regurgitation (MR) is a condition whereby the mitral valve leaks. As a result, a significant volume of blood is pushed backward into the left atrium. Left unattended, mitral regurgitation can lead to progressive enlargement of the heart and will lead to heart failure. Common causes for these leakages are usually either functional or degenerative. Conventional treatment of severe MR will be surgery, in the form of either mitral valve repair or replacement. However, this will require an open heart surgery. On occasions, the risk of surgery is high especially when there is coexisting medical conditions or advanced age.
Clinical Research Malaysia’s CEO discusses the need for Malaysia to focus on high quality pivotal trials rather than simply on a high number of trials. He shares with us the…
The National Heart Institute’s CEO portrays IJN as a national referral center for cardiovascular disease and declares: “IJN is equipped with the best in class technologies and is poised to…
“We believe the future lies with Universal health coverage and the formulation of one and only healthcare, with the merger of public and private sector under one reimbursement system” says…
PEMANDU’s Director for the Healthcare National Key Economic Area gives a thorough understanding of the various entry point projects that were implemented since 2010 to help Malaysia become a high…
Stefan Oschmann, President of the Emerging Markets at Merck and Co. described MSD as the dark horse of the emerging markets. How is MSD performing in Malaysia? Since the merger…
PhAMA was started in 1972 and now has most of the MNC players among its members which include 43 companies. How has the association evolved since its origin and what…
The pharmaceutical industry has been targeted as one of the key growth sectors for the Malaysian economy under the 10th Malaysia Plan, how successful in your opinion have the government…
Without a doubt, Malaysia shares all the major attributes of an emerging market, from the potential to expand market penetration to the increasing purchasing power of the population. So…
2011 marks the 10th anniversary of the company. Over that time you’ve enjoyed notable success including being the first Asian CRO to attain OECD GLP accreditation. Talk us through your…
Since its origin, Emerging Pharma has been helping foreign pharma companies to enter Malaysia. However, the Malaysian market is relatively small. Why should international pharma companies look to this country…
How would you describe the operating environment for foreign companies to use the services of Malaysian companies and how can you reassure these multinationals that sufficient intellectual property protection is…
Malaysia has good ethnic diversity, cost-effective infrastructure, and highly qualified principal investigators (PIs) and these elements have been in place for a long time. Why is now is the right…
See our Cookie Privacy Policy Here
